-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US75974E1038 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Target Price | 2.25 |
|---|---|
| Beta | 0.22 |
| Market Cap | 61M |
| PE Ratio | None |
| Dividend Yield | None |
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for RPHM using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025